Immunotherapy has had a tremendous impact on cancer treatment in the past decade, with hitherto unseen responses at advanced and metastatic stages of the disease. However, the aggressive brain tumor glioblastoma (GBM) is highly immunosuppressive and remains largely refractory to current immunotherapeutic approaches. The stimulator of interferon genes (STING) DNA sensing pathway has emerged as a next-generation immunotherapy target with potent local immune stimulatory properties. Here, we investigated the status of the STING pathway in GBM and the modulation of the brain tumor microenvironment (TME) with the STING agonist ADU-S100. Our data reveal the presence of STING in human GBM specimens, where it stains strongly in the tumor vasculature...
Background Activating the Stimulator of Interferon Genes (STING) adaptor incites antitumor immunity ...
Checkpoint blockade immunotherapies have demonstrated remarkable therapeutic success by overcoming t...
The long-term goal of cancer immunotherapy is to enhance intrinsic immune-specific anti-tumor respon...
While type-I interferons (IFNs) play critical roles in antiviral and antitumor activity, it remains ...
BackgroundNeuroblastoma (NB) is a childhood cancer for which new treatment options are needed. The s...
We recently reported that STING contributes to antiglioma immunity by triggering type I IFN inductio...
Although type I IFNs play critical roles in antiviral and antitumor activity, it remains to be eluci...
While STING (STimulator of INterferon Genes) has been shown to be essential for cytosolic DNA-trigge...
The advent of immunotherapy in recent years has shown the potential to revolutionize the treatment o...
Summary: Intratumoral (IT) STING activation results in tumor regression in preclinical models, yet f...
Stimulator of interferon genes (STING) is a cytosolic receptor that senses both exogenous and endoge...
Surgeons have unique in situ access to tumors enabling them to apply immunotherapies to resection ma...
SummarySpontaneous tumor-initiated T cell priming is dependent on IFN-β production by tumor-resident...
Pancreatic cancer is characterized by an immune suppressive stromal reaction that creates a barrier ...
Spontaneous tumor-initiated T cell priming is dependent on IFN-β production by tumor-resident dendri...
Background Activating the Stimulator of Interferon Genes (STING) adaptor incites antitumor immunity ...
Checkpoint blockade immunotherapies have demonstrated remarkable therapeutic success by overcoming t...
The long-term goal of cancer immunotherapy is to enhance intrinsic immune-specific anti-tumor respon...
While type-I interferons (IFNs) play critical roles in antiviral and antitumor activity, it remains ...
BackgroundNeuroblastoma (NB) is a childhood cancer for which new treatment options are needed. The s...
We recently reported that STING contributes to antiglioma immunity by triggering type I IFN inductio...
Although type I IFNs play critical roles in antiviral and antitumor activity, it remains to be eluci...
While STING (STimulator of INterferon Genes) has been shown to be essential for cytosolic DNA-trigge...
The advent of immunotherapy in recent years has shown the potential to revolutionize the treatment o...
Summary: Intratumoral (IT) STING activation results in tumor regression in preclinical models, yet f...
Stimulator of interferon genes (STING) is a cytosolic receptor that senses both exogenous and endoge...
Surgeons have unique in situ access to tumors enabling them to apply immunotherapies to resection ma...
SummarySpontaneous tumor-initiated T cell priming is dependent on IFN-β production by tumor-resident...
Pancreatic cancer is characterized by an immune suppressive stromal reaction that creates a barrier ...
Spontaneous tumor-initiated T cell priming is dependent on IFN-β production by tumor-resident dendri...
Background Activating the Stimulator of Interferon Genes (STING) adaptor incites antitumor immunity ...
Checkpoint blockade immunotherapies have demonstrated remarkable therapeutic success by overcoming t...
The long-term goal of cancer immunotherapy is to enhance intrinsic immune-specific anti-tumor respon...